A phase III, randomized, open-label study comparing the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate versus continuing stavudine or zidovudine in virologically suppressed HIV-infected children taking highly active antiretroviral therapy

Trial Profile

A phase III, randomized, open-label study comparing the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate versus continuing stavudine or zidovudine in virologically suppressed HIV-infected children taking highly active antiretroviral therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Stavudine; Zidovudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 08 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 09 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top